Fundación Medina

Fundación Medina.jpg

Contact information

Fundación Medina (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia)
Olga Genilloud, Directora Científica
Edificio Desarrollo Farmacéutico. Avda. Conocimiento 3, Parque Tecnológico Ciencias de la Salud
Granada
Granada
958993965
958846710
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Cell cultures
      • Drug discovery
      • Screening
    • Therapeutic areas
      • Genetic and rare diseases
      • Infectious diseases
      • Immunology
      • Oncology
      • Central nervous system
  • B. Agrifood Biotechnology
    • Agriculture / veterinary / environmental
      • Biologic control (plagues..) and bioestimulants of crops
      • Animal health / Veterinary
  • C. Industrial Biotechnology
    • Waste valorisation
  • D. Services
    • R&D services
      • Metabolomics
      • CRO / CMO / SMO
    • Professional services
      • Consultancy
      • Training and spreading

Fundación MEDINA is a non-profit public-private partnership between Merck Sharp and Dohme de España S.A., the Junta de Andalucía and the University of Granada, to discover innovative compounds and therapies for unmet medical needs.

Research activities at MEDINA are focused on:

I.Discovery of new compounds and therapies as new leads for drug development.

II. Contract Research Services: High throughput screening services for lead discovery, ADME/TOX, bioanalysis and metabolomics 

Products and services
  • New leads from microbial natural products in therapeutic areas with unmet medical needs.
  • License of natural product libraries
  • Drug discovery sreening platform
  • Highly automated screening services, including High Content Imaging.
  • Safety, adverse drug metabolism (ADME/TOX)and toxicity platform of drug candidates in development:
    • Cardiotoxicity: ion channels assays (hERG, Cav1.2, Nav1.5)
    • Drug metabolism assays(CYP inhibition and induction, drug stability and metabolite profiling)
    • Cytotoxicity
    • Genotoxicity (AMES Test)
    • Turbidimetry and solubility

Off-target interactions(neurotransmisor receptors, PPARs)

  • Bioanalysis and metabolomics (High resolution MS)
Areas of interest for future collaborations
  • Discovery of novel therapeutics from microbial natural products collections in: infectious diseases (including tuberculosis and parasitic diseases), oncology, immunoregulation and rare diseases.
  • Study of potential cardiovascular and neuronal safety risks, and drug-drug interactions of new leads in early stages of the drug-discovery process.
  • Metabolomic analysis and identification of metabolism biomarkers 

Biotech Sanitaria

Research Platforms
Product / Service Type Development phase
High throughput screening platform for drug discovery Screening/Drug Discovery Clinical Validation
Microbial Natural Product Libraries Screening/Drug Discovery Clinical Validation
Screening Cell lines & Animal Models Screening/Drug Discovery Preclinical
Mass spectrometry metabolomics Enabling Technologies, Screening/Drug Discovery R&D
Preclinical Safety Platform CRO, CMO Clinical Validation
Bioanalytical Platform CRO, CMO Clinical Validation
Chemical Isolation & Structural Elucidation of natural products CRO, CMO Clinical Validation
Microbial and Mammalian cell culturing CRO, CMO Clinical Validation
Diagnostics and Personalised Medicine
Product / Service Type Therapeutic area Development phase
Biomarkers Platform Biomarkers, Diagnostic Oncología Clinical Validation

Biotech Agroalimentaria

Other Technologies
Product / Service Aplication Development phase
MEDScreen platform Agrofood industry. Validation
MEDmicro platform Agrofood industry. Validation
MEDiscovery platform BEA provides services to companies and research institutions, in order to facilitate the implementation of initiatives and projects related to research and industrial developments in the field of cyanobacteria, microalgae and macroalgae biotechnology. R&D
MEDchemistry platform Agrofood industry. Validation